AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

2.450

+0.1606.99%

Volume:108.69K

Turnover:256.20K

Market Cap:442.93M

PE:-88.13

High:2.450

Open:2.300

Low:2.260

Close:2.290

52wk High:4.900

52wk Low:0.920

Shares:180.79M

Float Shares:121.21M

Volume Ratio:0.85

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.028

EPS(LYR):-0.028

ROE:-27.89%

ROA:-15.63%

PB:27.66

PE(LYR):-88.24

Loading ...

Overview Company News Filings

Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance

MT Newswires Live

Racura Oncology Says Potential of Proprietary Formulation to be Evaluated Early This Year; Shares Fall 7%

MT Newswires Live

Atomic Eagle And 2 More ASX Penny Stocks To Watch

Simply Wall St.

Racura Partners With US-University to Study Lead Asset in Osimertinib-Resistant Non-Small Cell Lung Cancer

MT Newswires Live

Racura Oncology Ltd-Racura Oncology Emory University Collaboration

THOMSON REUTERS

Racura Appoints Contract Research Organisation for Lung Cancer Trial

MT Newswires Live

Racura Oncology Ltd-Racura Oncology Appoints Bdd for Harness-1 Trial

THOMSON REUTERS

ASX Penny Stocks To Watch In December 2025

Simply Wall St.

Race Oncology Changes Name to Racura Oncology

MT Newswires Live

BRIEF-Race Oncology Completes A$3.22 Mln Private Placement

BUZZ-Australia's Race Oncology advances on premium placement

Race Oncology Ltd - Completes a$3.22M Private Placement at Issue Price of a$2.83 per New Share

THOMSON REUTERS

Race Oncology Secures Human Research Ethics Committee Approval for Non-Small Cell Lung Cancer Therapy Candidate Clinical Trial, Shares Fall 8%

MT Newswires Live

Race Oncology Ltd-Replacement Constitution

THOMSON REUTERS

Race Oncology to Launch Clinical Trials for Leukemia, Lung Cancer Therapy Candidate; Shares Jump 6%

MT Newswires Live

Race Oncology Ltd-Race Clinical Program Update

THOMSON REUTERS

ASX Opportunities: 3 Penny Stocks With Market Caps Over A$400M

Simply Wall St.

Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter

MT Newswires Live

TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours

Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":2.45,"timestamp":1770700320000,"preClose":2.29,"halted":0,"volume":108691,"delay":0,"changeRate":0.06986899563318784,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":180786237,"eps":-0.0278,"marketStatus":"Closed","change":0.16,"latestTime":"02-10 16:12:00 AEDT","open":2.3,"high":2.45,"low":2.26,"amount":256197,"amplitude":0.082969,"askPrice":2.45,"askSize":12351,"bidPrice":2.3,"bidSize":2641,"shortable":3,"etf":0,"ttmEps":-0.0278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.29,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.852367,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-15.63%","roe":"-27.89%","lyrEps":-0.027765,"volumeRatio":0.852367,"shares":180786237,"dividePrice":0,"high":2.45,"amplitude":0.082969,"preClose":2.29,"low":2.26,"week52Low":0.92,"pbRate":"27.66","psRate":"73.30","week52High":4.9,"institutionHeld":0,"latestPrice":2.45,"committee":-0.647679,"eps":-0.0278,"divideRate":0,"volume":108691,"delay":0,"ttmEps":-0.0278,"open":2.3,"prevYearClose":2.73,"prevWeekClose":2.25,"prevMonthClose":2.23,"prevQuarterClose":2.73,"fiveDayClose":2.25,"twentyDayClose":2.86,"sixtyDayClose":3.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609555609","title":"Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609555609","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609555609?lang=en_us&edition=fundamental","pubTime":"2026-02-06 13:11","pubTimestamp":1770354705,"startTime":"0","endTime":"0","summary":"Racura Oncology  is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2607008776","title":"Racura Oncology Says Potential of Proprietary Formulation to be Evaluated Early This Year; Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607008776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607008776?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:36","pubTimestamp":1769657790,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the potential of its proprietary formulation RC220 to prevent or slow resistance to osimertinib treatment in mutant epidermal growth factor receptor  lung cancer will be explored in the clinic early this year, according to a Thursday filing with the Australian bourse.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined EGFR mutations, the company said in an earlier filing.In-patient effect of the company's lead asset and anti-cancer agent RCDS1  on master cancer growth regulator MYC will be evaluated later in the year, the filing said.Shares of the company fell past 7% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2603042939","title":"Atomic Eagle And 2 More ASX Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603042939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603042939?lang=en_us&edition=fundamental","pubTime":"2026-01-16 03:02","pubTimestamp":1768503773,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a potential commodities supercycle, driven by surges in metals like gold and silver, investor interest in materials is on the rise. Amid this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at accessible price points. Despite their vintage name, these stocks can still provide surprising value when they are backed by strong financial health and solid fundamentals.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052001-choice2-main-header/1585186680440","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052001-choice2-main-header/1585186680440"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-aeu/atomic-eagle-shares/news/atomic-eagle-and-2-more-asx-penny-stocks-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-aeu/atomic-eagle-shares/news/atomic-eagle-and-2-more-asx-penny-stocks-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7128","BK7506","AEU.AU","WAF.AU","IGL.AU","PPS.AU","BK7143","BK7132","BK7045","BK7083","BK7067","VRS.AU","BK4211","BK7061","BK7503","MTO.AU","BK7104","BK7016","MXI.AU","VFY.AU","BK7055","BK7048","EGBN","BK7077","DSK.AU","RAC.AU","PPL.AU","EDU.AU","SSM.AU","BK7508","BK7050"],"gpt_icon":0},{"id":"2603755655","title":"Racura Partners With US-University to Study Lead Asset in Osimertinib-Resistant Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603755655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603755655?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:54","pubTimestamp":1768344883,"startTime":"0","endTime":"0","summary":"Racura Oncology  partnered with Emory University to study RCDS1 in osimertinib-resistant, epidermal growth factor receptor mutated  non-small cell lung cancer , according to a Wednesday filing with the Australian bourse.Osimertinib is the current standard of care treatment for NSCLC, the filing said.Under the deal, the company gets access to Emory's osimertinib-resistant cell and mouse NSCLC models and expertise, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2603653468","title":"Racura Oncology Ltd-Racura Oncology Emory University Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603653468?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:04","pubTimestamp":1768341897,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUE5NCQVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2593449591","title":"Racura Appoints Contract Research Organisation for Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449591?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:23","pubTimestamp":1766532203,"startTime":"0","endTime":"0","summary":"Racura Oncology  appointed Beyond Drug Development to support its HARNESS-1 Phase 1a/b clinical trial of drug candidate RC220 in patients with non-small cell lung cancer, for an estimated cost of AU$3.1 million, according to a Wednesday filing with the Australian bourse.The cost is dependent on the recruitment of patients, and the payment will be made after meeting key milestones, the filing said.The company expects to recruit the trial's first patient in the first quarter of 2026, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"gpt_icon":0},{"id":"2593446851","title":"Racura Oncology Ltd-Racura Oncology Appoints Bdd for Harness-1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446851?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:24","pubTimestamp":1766528694,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUE19NMZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAC.AU","BK7508"],"gpt_icon":0},{"id":"2592944597","title":"ASX Penny Stocks To Watch In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2592944597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592944597?lang=en_us&edition=fundamental","pubTime":"2025-12-18 03:02","pubTimestamp":1765998124,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape with sectors like Materials showing strength while Energy struggles, investors are keenly observing potential opportunities. Penny stocks, though an older term, still represent an intriguing area of investment by highlighting smaller or less-established companies that may offer value. By focusing on those with robust financials and clear growth prospects, investors can uncover promising opportunities in this niche segment.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-chn/chalice-mining-shares/news/asx-penny-stocks-to-watch-in-december-2025-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-chn/chalice-mining-shares/news/asx-penny-stocks-to-watch-in-december-2025-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7045","XAO.AU","BK7012","DSK.AU","XJO.AU","BK7506","BK7128","BK7055","SSM.AU","BK7077","BK7508","BK7016","BK7104","GWA.AU","BK7111","BK7143","BK7095","RAC.AU","UOS.AU","BK7132","BK7503","XKO.AU","PPS.AU","AAL.AU","BK7121","BK7067","MTO.AU","EZZ.AU","IGL.AU","EDU.AU","CHN.AU","WAF.AU","BK7048"],"gpt_icon":0},{"id":"2590439796","title":"Race Oncology Changes Name to Racura Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2590439796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590439796?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:21","pubTimestamp":1765261262,"startTime":"0","endTime":"0","summary":"Race Oncology  said that following a shareholder approval at its annual general meeting held on Monday, its name will change from Race Oncology to Racura Oncology, according to a Tuesday Australian bourse filing.This change has been recorded by the Australian Securities and Investments Commission  with effect from Dec .5, the filing added.The Australian Securities Exchange  will implement the change of name from the start of trading on Wednesday, while the ASX listing code \"RAC\" remains the same, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","RAC.AU","XJO.AU","BK4543","ASX.AU","BK7508","BK4141","ASX","BK7039","BK4107","ASIC","BK4526","XAO.AU","BK7067"],"gpt_icon":0},{"id":"2590793367","title":"BRIEF-Race Oncology Completes A$3.22 Mln Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590793367","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590793367?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:54","pubTimestamp":1765241689,"startTime":"0","endTime":"0","summary":"BRIEF-Race Oncology Completes A$3.22 Mln Private PlacementDec 9 (Reuters) - Race Oncology Ltd RAC.AX:COMPLETES A$3.22M PRIVATE PLACEMENT AT ISSUE PRICE OF A$2.83 PER NEW SHAREFurther company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2590364731","title":"BUZZ-Australia's Race Oncology advances on premium placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364731","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364731?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:58","pubTimestamp":1765238338,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Race Oncology advances on premium placement** Shares of Race Oncology RAC.AX rise as much as 10.1% to A$2.94, their largest intraday pct jump since November 17. ** Biopharmaceutical firm receives commitments to raise A$3.22 million  via a placement. ** Placement issue price at A$2.83 per share, a 6% premium to stock's last close. ** Says funds will be used to advance the commencement of co's HARNESS-1 phase 1 trial for non-small cell lung cancer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE17Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAC.AU","BK7508"],"gpt_icon":0},{"id":"2590236606","title":"Race Oncology Ltd - Completes a$3.22M Private Placement at Issue Price of a$2.83 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236606","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236606?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:59","pubTimestamp":1765231198,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2586866362","title":"Race Oncology Secures Human Research Ethics Committee Approval for Non-Small Cell Lung Cancer Therapy Candidate Clinical Trial, Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586866362","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586866362?lang=en_us&edition=fundamental","pubTime":"2025-11-26 09:42","pubTimestamp":1764121361,"startTime":"0","endTime":"0","summary":"Race Oncology  received human ethics approval from the St. Vincents Hospital, Melbourne human research ethics committee to begin a phase 1a/b clinical trial assessing the safety, tolerability and pharmacokinetics of its RC220 therapy candidate, in combination with osimertinib, in patients with non-small cell lung cancer that have activating epidermal growth factor receptor mutations, according to a Wednesday Australian bourse filing.Phase 1a will begin with a circulating tumor DNA screening stage, followed by dose escalation, where between 12 and 40 patients will receive intravenous infusion of RC220 on the first day of a 21-day cycle in combination with standard-of-care osimertinib. The study will start with three single-patient cohorts before transitioning to a larger number of patient cohorts to identify the maximum tolerated dose of RC220.In the Phase 1b stage, 40 patients will be randomized to one of two treatment dose levels.Monash Health in Victoria will start enrolling patients","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2585437206","title":"Race Oncology Ltd-Replacement Constitution","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437206?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:56","pubTimestamp":1763956598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUE3S1NXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2584804690","title":"Race Oncology to Launch Clinical Trials for Leukemia, Lung Cancer Therapy Candidate; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584804690","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584804690?lang=en_us&edition=fundamental","pubTime":"2025-11-17 09:55","pubTimestamp":1763344502,"startTime":"0","endTime":"0","summary":"Race Oncology (ASX:RAC) said it will launch new clinical trials for its RC220 therapy candidate in acute myeloid leukemia and non-small cell lung cancer, according to a Monday Australian bourse filing","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"gpt_icon":0},{"id":"2584696759","title":"Race Oncology Ltd-Race Clinical Program Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584696759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584696759?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:12","pubTimestamp":1763331145,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUEBRCZJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2583469589","title":"ASX Opportunities: 3 Penny Stocks With Market Caps Over A$400M","url":"https://stock-news.laohu8.com/highlight/detail?id=2583469589","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583469589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:02","pubTimestamp":1762974138,"startTime":"0","endTime":"0","summary":"The Australian market saw a flattish green day, with the ASX200 inching up by one-tenth of a percent as investors remained cautious amidst ongoing global economic uncertainties and fluctuating commodity prices. In such conditions, discerning investors often seek opportunities in lesser-known segments like penny stocks, which despite their outdated moniker, continue to offer intriguing prospects for growth. These stocks typically represent smaller or newer companies that can combine attractive...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-wia/wia-gold-shares/news/asx-opportunities-3-penny-stocks-with-market-caps-over-a400m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-wia/wia-gold-shares/news/asx-opportunities-3-penny-stocks-with-market-caps-over-a400m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DSK.AU","XJO.AU","BK7067","BK7077","LBL.AU","BK7506","BK7095","XKO.AU","BK7088","WIA.AU","BK7104","SSM.AU","XAO.AU","BK7045","FWD.AU","BK7055","STK.AU","IGL.AU","AAL.AU","MXI.AU","WAF.AU","BK7508","BK7128","BK7503","MTO.AU","PPS.AU","BK7014","RAC.AU","BK7143","BK7016"],"gpt_icon":0},{"id":"2579848629","title":"Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2579848629","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579848629?lang=en_us&edition=fundamental","pubTime":"2025-10-31 09:49","pubTimestamp":1761875382,"startTime":"0","endTime":"0","summary":"Race Oncology  said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2575576206","title":"TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2575576206","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575576206?lang=en_us&edition=fundamental","pubTime":"2025-10-16 09:43","pubTimestamp":1760579038,"startTime":"0","endTime":"0","summary":"TrivarX has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics.Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging  equipment to visualise and monitor tumour growth without the need for radiation or surgical procedures.The platform – which utilises stable isotope labelling to identify replicating cells within the brain – will allow TrivarX to advance a targeted opportunity in the high-growth global market for brain imaging with a key focus on safety, precision and treatment monitoring.TrivarX will receive assistance from Nucleics founder Dr Daniel Tillett, who has offered to provide ongoing support and technical advice around preclinical and clinical studies.Dr Tillett is a prominent biotechnology entrepreneur, investor, and innovator with more than 25 years’ ex","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/TrivarX-ASX-TRI-Acquire-Stabl-Im-Diagnostic-Technology-Early-Detection-Metastatic-Brain-Tumours.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/TrivarX-ASX-TRI-Acquire-Stabl-Im-Diagnostic-Technology-Early-Detection-Metastatic-Brain-Tumours.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/trivarx-to-acquire-stabl-im-diagnostic-technology-for-early-detection-of-metastatic-brain-tumours/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/trivarx-to-acquire-stabl-im-diagnostic-technology-for-early-detection-of-metastatic-brain-tumours/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["MRI.AU","TRI.AU","RAC.AU","BK7057","BK7094","BK7508","BK7067"],"gpt_icon":0},{"id":"2573660905","title":"Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism","url":"https://stock-news.laohu8.com/highlight/detail?id=2573660905","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573660905?lang=en_us&edition=fundamental","pubTime":"2025-10-05 02:20","pubTimestamp":1759602017,"startTime":"0","endTime":"0","summary":"Race Oncology (ASX:RAC) is drawing fresh attention after revealing a breakthrough discovery on how its leading drug, bisantrene, fights cancer. This scientific milestone highlights new prospects for targeted therapies and business growth.\nSee our latest analysis for Race Oncology.\nFollowing the news of this breakthrough, Race Oncology shares saw strong momentum, briefly surging nearly 30% over the week. While recent excitement has moderated, the company’s total shareholder return of over 1%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAC","RAC.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}